Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1

Interventions

Cyclophosphamide 55fludarabine 29Methotrexate 25blinatumomab 22Dexamethasone 22Cytarabine 21Vincristine 20venetoclax 18fludarabine phosphate 15Specimen Handling 15Whole-Body Irradiation 13Stem Cell Transplantation 11Biopsy 11Tacrolimus 10Prednisone 10Mycophenolic Acid 10Mercaptopurine 10Daunorubicin 10Thiotepa 9Rituximab 9Melphalan 9Immunotherapy, Adoptive 9Doxorubicin 8pegaspargase 7Magnetic Resonance Spectroscopy 7Inotuzumab Ozogamicin 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7Calcium Dobesilate 7ponatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Random Allocation × Clear all
NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡